What are you looking for?
All Filters
Therapeutic Area
Therapeutic Area
Date Published
Date published

Lp(a) testing may improve CVC risk assessment in primary and secondary prevention settings

 

novartis_lp-a_illustration_digitala4_250605.png

Figure is adapted from Nurmohamed et al. Eur J Prev Cardiol. 2022;29(5):769-776

 

 

Following Lp(a) testing 

 

  • One in three patients with very elevated Lp(a) levels* were reclassified into a higher primary prevention risk category 

  • 50% of all patients with very elevated Lp(a) levels* were reclassified into a higher seconday prevention risk category 

 

 

SCORE: Conroy et al. Eur Heart J 2003;24:987–1003; https://www.heartscore.org/en_GB(Last accessed July 2024) 

SMART: Dorresteijn et al. Heart 2013;99:866–872; https://u-prevent.com/calculators/smartScore(Last accessed July 2024); 

*> 99th percentile, mean Lp(a) of 460 nmol/L. Back to the main page

 

Back to the main page